Key Takeaways
- •On February 27, 2025, Dr.
- •On January 21, 2025, scientists published a study on two novel MVA-vaccines that express a chimeric protein containing several antigens from different Chlamydia trachomatis serovars.
- •On November 20, 2024, Dr.
Varicella Zoster Virus: gE, IE-62 and IE-63 Essential for Infection
On February 27, 2025, Dr. Lilian Schoefer reported that the proteins gE, IE-62 and IE-63 are essential for an infection with the Varicella Zoster Virus. These proteins play critical roles in membrane fusion, gene transactivation and immune evasion.
Vaccines Against Chlamydia trachomatis: Immunogenicity Analysis via Peptide Pool
On January 21, 2025, scientists published a study on two novel MVA-vaccines that express a chimeric protein containing several antigens from different Chlamydia trachomatis serovars. To analyze the immune responses, the researchers developed a peptide pool of the chimeric protein.
Beta-Amyloid Peptides: The Secret Stars Behind Lecanemab
On November 20, 2024, Dr. Schoefer highlighted that the fact that Alzheimer's patients can now benefit from Lecanemab is thanks not only to the hard-working scientists in this research area but also to the beta-amyloid peptides. Peptides were instrumental in the development process of this drug.
Reflecting on an Inspiring SITC2024
On November 11, 2024, the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) took place in Houston, Texas. The event allowed researchers to share the latest advancements in peptide synthesis with the cancer immunotherapy community.
Esophagogastric Adenocarcinoma: Tumor-Associated Antigens, Immune Responses and HLA-I Expression
On October 18, 2024, researchers identified the most significant tumor-associated antigens in esophagogastric adenocarcinoma. They determined how endogenous T cells and antibodies reacted to them and also investigated the influence of HLA homozygosity.
Quality Control of Peptide Pools in Personalized Cancer Therapy
On August 28, 2024, researchers at the BAM in Berlin evaluated the effectiveness of UHPLC coupled with two different detectors for quality control of peptide pools. The quality of peptide pools is crucial for the accuracy of immunotherapies, but the quality control of these complex products remains a challenge.
Neoantigen-Specific T-Cells in TIL Therapy
On July 29, 2024, Dr. Schoefer reported on the newly approved Lifileucel, which stimulates tumor-infiltrating lymphocytes (TILs) unspecifically. Researchers are now investigating the degree to which neoantigens contribute to tumor regression under TIL therapy.
Peptide Pools: Powerful Tools in Immune Research
On June 19, 2024, peptide pools were described as covering long peptide sequences and even entire proteins. They can stimulate antigen-specific CD4+ and CD8+ T cells efficiently and cost-effectively.
IMMUNOLOGY 2024: High-Profile Journals and Three Plush Elephants
From May 4th to 6th, the IMMUNOLOGY2024 conference was held at the AAI Meeting in Chicago, Illinois. This is the leading annual immunology event worldwide.
Tumor Immunology Meets Oncology: Insights from the TIMO XVIII Symposium
On May 14, 2024, the Symposium Tumor Immunology meets Oncology XVIII (TIMO XVIII) took place at the Old Townhall in Brandenburg at the Havel, Germany. It served as a nexus for leading scientists, clinicians and young researchers from 13 different countries.
Potent PRAME-Specific T Cell Receptor for Adoptive T Cell Therapy
On March 6, 2024, researchers led by Nadja Sailer from Medigene Immunotherapies GmbH found a highly effective PRAME-specific T cell receptor for adoptive T cell therapy. This represents an important step forward in the treatment of melanoma and other solid tumors.
Endotoxin Contamination Triggers Severe Symptoms
On February 22, 2024, Dr. Schoefer reported that endotoxin originates from the outer membrane of gram-negative bacteria. When endotoxin is present in vaccines and other injectable drugs, pyrogenic reactions can occur, ranging from fever and chills to fatal septic shock.
Students Meet Peptides: Learning About Peptide Synthesis
On January 31, 2024, students participated in a career orientation project week to learn more about peptide synthesis.
FACS Analysis Showed: CMV-Specific T Cells Respond to Leukemia Antigen
On November 18, 2023, using FACS analysis and peptide pools, researchers tested whether reactivation of the cytomegalovirus influences T cell immunity against Wilms tumor 1 and thus against leukemia cells.
Epstein-Barr Virus: Mechanisms of Cancer Development Decoded
On October 4, 2023, Dr. Schoefer reported that over 90 percent of adults worldwide are infected with the Epstein-Barr virus (EBV). The virus belongs to the herpes viruses and stays in the body for a lifetime.
IMMUNOLOGY 2023: Workshop on Peptide Pools
On July 12, 2023, Dr. Oliver Kreuzer reported on a workshop about peptide pools at the IMMUNOLOGY 2023 conference.
Exponential Increase in the BA.5 Omicron Subtype
On June 24, 2022, Dr. Kreuzer reported that Omicron was accounting for over 99% of all SARS-CoV-2 infections in Germany. Since calendar week 14, an exponential increase in the BA.5 Omicron Subtype was reported. The BA.5 Omicron Peptide Pool was synthesized immediately.
Personalized Cancer Vaccines
On April 7, 2021, it was reported that peptides & elephants received 1 Million USD funding for the development of the high parallel Ultrasound Peptide Synthesis, USPS.
For more information on peptide research and tools, visit our Peptide Glossary or check out the Latest Peptide News. You can also explore our blog for further updates.
